Key legal victory: In a drug pricing lawsuit with NHIS, the appellate court (Seoul High Court) overturned the first-instance loss (approx. KRW 121.5bn) and ruled in favor of the company, ordering the plaintiff to return approx. KRW 24.1bn. NHIS appealed to Supreme Court, final decision pending.
Share cancellation: Board resolved on Feb 27, 2026 to cancel 423,047 common shares (2.6% of outstanding), executed on Mar 9, enhancing shareholder value.
Dividend: FY2025 cash dividend of KRW 610 per share (total ~KRW 9.7bn); 30 consecutive years of cash dividends.
Financial position: Total assets KRW 563.1bn, debt KRW 104.0bn, equity KRW 459.2bn, debt-to-equity ratio 22.6% (stable).
R&D investment: Q1 R&D expense KRW 8.7bn (11.7% of revenue); UI064 for respiratory disease in Phase 3 clinical trial.
License agreement: Exclusive supply deal with Teva for Clanza CR in Russia etc.; export revenue USD 3.3mn received.